Harbert Fund Advisors, Inc. Fennec Pharmaceuticals Inc. Transaction History
Harbert Fund Advisors, Inc.
- $33.3 Billion
- Q2 2025
A detailed history of Harbert Fund Advisors, Inc. transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Harbert Fund Advisors, Inc. holds 287,614 shares of FENC stock, worth $2.36 Million. This represents 7.16% of its overall portfolio holdings.
Number of Shares
287,614
Previous 466,869
38.4%
Holding current value
$2.36 Million
Previous $2.84 Billion
16.04%
% of portfolio
7.16%
Previous 3.22%
Shares
7 transactions
Others Institutions Holding FENC
# of Institutions
82Shares Held
14.2MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$33.5 Million0.98% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$19.8 Million33.54% of portfolio
-
Solas Capital Management, LLC Darien, CT2.23MShares$18.4 Million12.03% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$9.76 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA967KShares$7.95 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $214M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...